India’s Serum Institute seeks financial help from the government


FILE PHOTO: Adar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India poses for a picture at the Serum Institute of India, Pune, India, 30 November 2020. REUTERS/Francis Mascarenhas/File Photo
FILE PHOTO: Adar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India poses for a picture at the Serum Institute of India, Pune, India, 30 November 2020. REUTERS/Francis Mascarenhas/File Photo

RESTRICTIONS on exporting its Covid vaccines have left India’s Serum Institute needing financial help from the government, its CEO said, with the world’s largest jab manufacturer under pressure at home from soaring cases.

Prime minister Narendra Modi’s government last month put the brakes on exports of AstraZeneca jabs made by the Serum Institute of India as the nation of 1.3 billion people experienced an alarming new wave of infections.

The pressure has meant production capacity at Serum Institute is ‘very stressed, to put it quite frankly’, the firm’s CEO Adar Poonawalla told NDTV .

“The globe needs this vaccine and we are prioritising the needs of India at the moment and we are still short of being able to supply… to every Indian that needs it.”

The company now requires additional funding of Rs 30 billion ($408 million) to ramp up capacity and has asked the government for financial help, he added.

“This was never budgeted or planned initially because we were supposed to export and get the funding from export countries but now that that is not happening, we have to find other innovative ways to build our capacity,” Poonawalla said.

Serum Institute, which produces over two million doses of Covishield — the local name for the AstraZeneca vaccine — a day, is providing the jab at a subsidised rate of around Rs 150 to India, significantly less than what it charges for exports.

“The price that is set is profitable, however it is not profitable enough to re-invest substantially in building capacity,” Poonawalla said.

Serum Institute — which recorded annual revenues of over $800 million in 2019-20 — has seen its profile soar since the pandemic, with several countries including Britain, Brazil and South Africa clamouring to buy its vaccine.

The firm has also struck a deal to supply 200 million doses to Covax, a World Health Organization-backed effort to procure and distribute inoculations to poor countries.

The country began vaccinating people aged over 45 last week, aiming to inoculate 300 million people by August. So far it has administered around 87 million shots.

India recorded almost 116,000 new cases in 24 hours on Wednesday (7), with New Delhi and other cities imposing new curbs on movement and public gatherings in response to the spike.

>

Adblocker detected! Please consider reading this notice.

We've detected that you are using an Adblocker which is preventing the page from fully loading.

We don't have any banner, Flash, animation, obnoxious sound, or popup ad. We do not implement these annoying types of ads!

We depend on the revenues generated to operate the site, and continue to bring you great news content

Please add www.easterneye.biz to your ad blocking whitelist or disable your adblocking software.

×